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Viremic Relapse after HIV-1 Remission in a Perinatally  
Infected Child
To the Editor: We previously reported1 the re-
mission of human immunodeficiency virus type 
1 (HIV-1) in a perinatally infected child — the 
“Mississippi Child.” After receiving antiretroviral 
therapy (ART) between 30 hours and 18 months 
of age, this child had persistently undetectable 
plasma HIV-1 viremia for 12 months in the ab-
sence of HIV-1–specific immune responses. At the 
time of the initial case report, it was uncertain 
whether HIV-1 reservoirs were established that 
could lead to rebound viremia.
After the first report, the child had persis-
tently undetectable plasma HIV-1 RNA levels, as 
assessed by means of standard clinical assays, 
with normal CD4+ and CD8+ T-cell counts. 
Plasma viremia also remained undetectable 
through 21.9 months after the discontinuation 
of ART on ultrasensitive single-copy viral-load 
assays (<0.4 and <0.5 copies per milliliter).
During routine clinical follow-up at 46.4 months 
of age (27.6 months after the discontinuation of 
ART), the plasma viral load rebounded to 16,750 
copies per milliliter; this was confirmed with 
repeat testing (Fig. 1A). The child did not have 
symptoms or signs of an acute retroviral syn-
drome or incident illnesses (including Epstein–
Barr virus infection or cytomegalovirus infec-
tion) and had not received any vaccines. 
Epidemiologic risk factors for reinfection with 
HIV-1 such as through breast milk, premasti-
cated food, or sexual abuse were not identified. 
Within 72 hours after the reinitiation of ART, 
the plasma viral load dropped to 2658 copies per 
milliliter (Fig. 1A), circulating CD4+ T-cell levels 
increased to 43%, and the ratio of CD4+ T cells 
to CD8+ T cells normalized.
During the period of virologic remission, 
HIV-1 DNA was intermittently detected in circu-
lating unfractionated peripheral-blood mono-
nuclear cells (PBMCs) and cells enriched for 
resting and activated CD4+ T cells. HLA typing 
confirmed the patient identity of the cellular 
DNA used for HIV-1 DNA measurements. The 
median number of copies of HIV-1 DNA in un-
fractionated PBMCs and resting and activated 
CD4+ T cells before rebound viremia was 2.7 per 
million cells (interquartile range, 2.2 to 3.4), 
3.5 per million cells (interquartile range, 2.1 to 
4.4), and 3.3 per million cells (interquartile range, 
1.8 to 5.5), respectively. However, replication-
competent viral reservoirs remained undetectable 
throughout follow-up in a cumulative 64 million 
cultured resting CD4+ T cells.
HIV-1–specific antibody and cell-mediated 
immune responses were not detected through 
21.9 months after the discontinuation of ART 
but were detected at viremic rebound by means 
of enzyme-linked immunosorbent assay. The 
findings were confirmed by Western blot testing 
(1:10 dilution), which revealed reactivity to HIV-1 
Env (gp160) and Gag (p24); 72 hours later, West-
ern blot testing revealed reactivity to HIV-1 Env 
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(gp160, gp120, and gp41), Gag (p55, p24, and 
p17), and Pol (p66). The lack of detectable re-
sponses to p31 integrase was compatible with 
rebound viral replication of at least 1 month but 
less than 2 months.3
Before viremic rebound, sequencing attempts 
were unsuccessful. Single-genome amplification 
and sequencing of full-length HIV-1 Env directly 
from rebounding plasma virus revealed 98.6% 
sequence identity to maternal plasma viral se-
quences collected 24 months after delivery (Fig. 
1B). Diversity was 0.1%, consistent with values 
seen in transmitted founder viruses in mother-
to-child HIV-1 transmission4 and a lack of ongo-
ing virus replication during the period of HIV-1 
remission. Phenotypic and genotypic analysis of 
the HIV-1 Env sequence from rebounding virus 
showed R5 tropism.
In conclusion, the return of HIV-1 viremia 
after a substantial period of viral quiescence is 
consistent with the model of HIV-1 latency in 
which long-lived resting memory CD4+ T cells 
were generated during routine immunologic 
memory formation, though other reservoirs are 
also possible. To the best of our knowledge, this 
child received ART between 30 hours and 18 
months of age. Whether earlier initiation or a 
longer duration of ART, alone or combined with 
immunotherapeutic strategies, would have af-
fected the duration of remission is unknown. 
The findings in this case and others5 provide 
insight on how very early treatment may restrict 
but not eradicate HIV-1 reservoirs. Additional 
studies are under way to test this hypothesis and 
to determine whether ART alone will enable 
longer-term HIV-1 remission. Until these studies 
Figure 1. Plasma HIV-1 Load and Phylogenetic Analyses.
Panel A shows human immunodeficiency virus type 1 
(HIV-1) RNA levels during antiretroviral treatment (ART), 
while the child was not receiving ART, and after the re-
initiation of ART. Solid circles indicate detectable HIV-1 
RNA, and open circles undetectable HIV-1 RNA; the 
shaded area indicates the limit of detection of the plas-
ma viral-load assay. 3TC denotes lamivudine, AZT zido-
vudine, EFV efavirenz, LPV/r ritonavir-boosted lopina-
vir, and NVP nevirapine. Panel B shows phylogenetic 
analyses of maternal plasma viral sequences amplified 
from a maternal plasma sample collected 24 months 
after delivery of the infant (M01) and during viral re-
bound in the infant (B01) (shaded area). The neighbor-
joining tree depicts full-length gp160 env sequences. 
Four previously described2 HIV-1 clade B–infected 
mother–infant pairs were included in the analysis for 
comparison of interpatient diversity and relatedness 
between mother and infant.
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are completed, initiation of ART as early as pos-
sible in infants and continuation without inter-
ruption seem prudent.
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